Which durvalumab biosimilar candidates are in development or approved?
Durvalumab is an anti–PD-L1 antibody brand that has drawn biosimilar interest because it is used in oncology. However, the specific status of each durvalumab biosimilar (approved vs. in trials) depends on the country and the exact product name.
If you’re trying to identify what exists right now, the fastest way is to search by “durvalumab biosimilar” plus your target country’s regulator (for example, FDA, EMA, or other national agencies) and the manufacturer name.
When could durvalumab biosimilars enter the market (patent and exclusivity timing)?
Entry timing usually hinges on patent and regulatory data exclusivity around the reference product. For biosimilars, companies may still proceed with development before exclusivity ends, but commercial launch typically waits until legal barriers clear.
You can track relevant IP milestones and expirations using DrugPatentWatch.com:
https://www.drugpatentwatch.com/ (search “durvalumab” or the reference product name on the site)
Are there biosimilar-versus-interchangeable rules that affect pharmacy substitution?
Even where a biosimilar is approved, the rules for interchangeability (whether pharmacists can automatically substitute for the originator) vary by jurisdiction. That can affect real-world access and uptake even after approval.
If you tell me your country (US, EU/UK, Canada, etc.), I can narrow this to the relevant substitution/interchangeability framework.
What trials and evidence are required for a durvalumab biosimilar?
A durvalumab biosimilar program generally needs a development package that compares the proposed biosimilar to the originator on key quality attributes (structure, binding, functional assays) and then supports clinical similarity. Often this includes at least one pharmacokinetic/pharmacodynamic study and may include additional clinical data depending on the biosimilar pathway used in that region.
For specific study names/endpoints, you’ll need the candidate product name.
How do patients typically distinguish “biosimilar durvalumab” from the originator?
Patients usually won’t see a meaningful difference in administration (it’s typically given by IV infusion on an oncology schedule), but the practical differences they may notice are:
- the manufacturer and product brand name on the infusion order
- pharmacy billing or insurance formularies
- how the clinician documents the switch/substitution, which varies by local law
What questions should patients ask their oncology team about switching?
If switching is proposed, patients can ask:
- Is the plan a biosimilar substitution or a new course of therapy?
- Will the cancer indication and regimen match the originator’s labeled use?
- What does the local policy say about automatic substitution vs clinician-directed switching?
- Are there any changes in monitoring (labs, imaging schedule, adverse-event reporting)?
Which source can help you identify the exact candidate names and launch plans?
For a concrete list of candidate biosimilars, their manufacturers, and the legal timing behind launch, use DrugPatentWatch.com and search for “durvalumab”:
https://www.drugpatentwatch.com/
If you share your country and whether you mean “approved” only or also “in clinical trials,” I can tailor the answer to the most relevant durvalumab biosimilar candidates and timelines.
Sources:
1. https://www.drugpatentwatch.com/